WHO WE ARE

WHO WE ARE

Headquartered in New Jersey, we are committed to raising the standard of care for cancer patients with first-in-class cancer treatments that improve lives and clinical outcomes for millions of patients in need.

Our late-stage, first-in-class asset, plinabulin, is an easy-to-use differentiated tubulin binder which induces dendritic cell maturation and T cell activation, and targets tumor vasculature. Plinabulin is being developed in combination with standard of care (SOC) agents as a “pipeline in a drug” in a number of cancer indications, as a direct anti-cancer agent:

1. Second- or third-line EGFR-wild type advanced and metastatic NSCLC: Combination of Plinabulin and docetaxel showed significant and long-term overall survival benefits compared to SOC docetaxel, in a global phase 3 study (Shi et al 2024 Lancet RM)
2. Second- or third-line metastatic NSCLC with disease progression after prior PD-1/PD-L1 inhibitor therapy: Combination of Plinabulin with pembrolizumab and docetaxel (2024 ESMO poster, 2024 SITC poster)
3. Multiple cancer types with disease progression after prior immunotherapy: Combination of Plinabulin with radiotherapy and PD-1 inhibitors (2023 SITC poster)
4. First-line ES-SCLC: Combination of Plinabulin with etoposide/platinum and pembrolizumab (NCT05745350), as well as
5. Prevention of chemotherapy-induced neutropenia (CIN) with clinically meaningful results: Plinabulin as a monotherapy or in combination with G-CSF. (Blayney et al 2020 JAMA Oncology; Blayney et al 2022 JAMA Oncol Open; 2021a Blayney ASCO; 2021b Blayney ASCO; 2021c Blayney ASCO)

We are an equity owner of SEED Therapeutics, which is a leading Targeted Protein Degradation (TPD) 2.0 company focusing on developing novel “molecular glues” for breakthrough therapeutics. We remain part of SEED’s continued success in revolutionizing drug discovery.